



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Company Showcase



Moderator & Speakers



Dan Hargrove, JD

Moderator

*Co-Founder & Past President
LumaBridge, LLC*



James Barlow, MBA

*Chief Executive Officer
ImmunoGenesis, Inc.*



Lance Black, MD, MBID

*Chief Clinical Strategy Officer
Prana Thoracic, Inc.*



Speakers, continued



Kirk Dorius, JD

*Chief Executive Officer
Atom Mines, LLC*



Laura Indolfi, PhD

*Founder & Chief Executive Officer
PanTher Therapeutics, Inc.*



Upendra Marathi, PhD, MBA

*President & Chief Executive Officer
7 Hills Pharma*

Therapeutics on Target: Attacking Cancer at the Source™

PanTher
Therapeutics

Company Overview
CPRIT Conference 2023

Laura Indolfi
Founder and CEO

lindolfi@panthertx.com
www.panthertx.com

Clinical-Stage Oncology Company Transforming Targeted Treatments

Venture-Backed Start-Up Leveraging Minimally Invasive Procedures



De-risked
lead program

Early clinical evidence that **PanTher's** lead program, PTM-101, is effective at reducing the size pancreatic tumors



Fast to market
potential

FDA supports 505(b)(2) pathway, taking advantage of known and approved active pharmaceutical ingredients



Significant
pipeline
opportunity

Platform can be applied to numerous drugs where therapeutic potential is limited by safety issues (e.g., approved effective drugs, novel drugs in development)



Leadership
position

CEO developed **PanTher's** novel technology over the past 11 years, which is supported by broad foundational IP with issued claims



Financing

PanTher is currently funded through 2024 and intends to initiate a Series B financing in Q1 2024.

Leadership Understands Industry, Know-How, and Drug Development



Laura Indolfi, PhD
Founder & CEO
MIT, Sloan; TED Fellow



Leslie S Sloan, PhD
*SVP of Development
and Operations*



John Edwards
Executive Chair



Dan Wildman
*Board Member and
Strategic Advisor*



Technology Endorsed by Renowned KOLs



Thomas Clancy
MD, FACS

Surgical Oncologist
Dana-Farber Cancer Institute



Theodor Hong
MD

Radiation Oncologists
Massachusetts General Hospital



Jason Fleming
MD, FACS

Surgical Oncologist
Moffitt Cancer Center



Ching-Wei Tzeng
MD, FACS


Surgical Oncologist
MD Anderson Cancer Center




Sagittari™: Enhancing Clinical Outcomes through Local Treatment

Unlocking the full potential of oncology drugs by engineering sustained direct-to-tumor treatments

Systemic



Local



Direct administration of proven drugs to the tumor area



Continuous, prolonged drug exposure




Increased **tissue retention**



Reduced off-target effects enabling combination therapies


Sagittari™ Yields Modular Customized Solutions



Solid Tumor Opportunities

- There are **>9 million addressable cases** annually indicated for surgery

Global Cases Indicated for Surgery (000s)



Every staging / diagnostic procedure is a potential entry point for our platform solutions

PTM-101: ~\$2B Opportunity in Neoadjuvant Pancreatic Cancer


1st Clinical Program

Route of Administration


Laparoscopy



Patch



Paclitaxel



Form Factor

Therapeutic

Lead Indication:
Pancreatic Cancer

- PTM-101 eligible for drug reimbursement at **\$25,000+** via J Code
- ~50% of pancreatic cancer patients are eligible for laparoscopy
- Neoadjuvant treatment is a **\$1.9 Billion** opportunity in US and EU alone
- Upside: Adjuvant treatments could double the market opportunity

PTM-101: Lead Product for Pancreatic Cancer

Leverage SOC diagnostic procedure to start early treatment with clinically validated chemo to reduce tumor volume

Phase I Clinical Trial Demonstrate Encouraging Results



Will Physicians
Recommend It?



Does It Fit Into Current
Treatment Regime?



Is It Safe For
Patients?

Promising early clinical data for first dose cohort

- ✓ **Local response** demonstrated in initial cohort of patients
- ✓ **Excellent safety profile**, well tolerated in all patients with no SAEs, no peritonitis, pancreatitis, infection, or hematologic toxicity.
- ✓ **No detectable** level of drug systemically at any tested timepoint.
- ✓ **Minimal increase in OR time** for PTM-101 deployment (<20min).

Strong Response in the Direction of Drug Release for all Patients



Diagnostic CT




**2 weeks
Post-Implant**




**24 weeks
Post-Implant**

PTM-101: Development Timeline and Key Milestones

Multiple data readouts and value triggers over next two years



Building PanTher: Our History and Plan Ahead



CPRIT-Driven Highlights In the First Year

➤ **Attract talent** to increase skillset and execute on the vision



Leslie S Sloan, PhD
*SVP of Development
and Operations*



Tucker Folsom
Associate Scientist



Caltech

Bringing the Fight against Cancer to the Target (and Times Square)





7 HILLS
P H A R M A

***Pioneering Integrin Agonists to
Augment the Power of
Immunotherapy***

Upendra Marathi
President & CEO

upendra@7hillspharma.com

THE INFORMATION CONTAINED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY,
AND THIS DOCUMENT IS NOT AN OFFERING OR SOLICITATION FOR THE SALE OF SECURITIES

7 Hills has deep roots in Texas

Founded with
Local Technology



Local Executives




Local Capital

~\$8 million angel investment

CPRIT/NIH

~\$27 million Sponsored Research

Local
Development



Solid Tumors

Problem:
90% of patients resistant to checkpoint inhibitors


Solution: Alintegimod



Blood cancers

Problem:
>70% of patients will not find a match for curative stem cell transplant


Solution: 7HP935




Outcomes

- Improved patient survival
- Low toxicities
- Low cost

Integrin mediated cell adhesion is critical in the major steps of an immune response



Risk diversified pipeline leverages >\$20 million in active non-dilutive funding



Total Non-dilutive funds ~\$27 million

Problem: No effective treatment options for patients that fail immune checkpoint blockade

Situation



Solid Tumors

- >\$30 Billion on PD-1 inhibitors
- >90% of patients progress on PD-1 inhibitors

Complication


- Ipilimumab + Nivolumab may provide 27% ORR
- Generate new T cells,
- But, ~60% Grade >3 AEs

7 Hills Solution


- Alintegimod, a dual $\alpha 4\beta 1$ and $\alpha L\beta 2$ agonist
- A means to augment co-stimulation without added toxicity

Solution: Augment Co-stimulation

Increase Cancer Immune Checkpoint Inhibitor effectiveness



Increase Generation of New Melanoma Specific T cells



Hickman et al, J. Clin. Inv. 2022

Problem: No effective treatment for patients who can't get a bone marrow transplant

Situation



Leukemia

- Mortality of 25 to 50%
- Most common childhood cancer

Complication

- Myeloablative therapy + Stem cell transplant can be curative
- >70% of patients will not find a matched donor
- Umbilical Cord blood is an alternative source of cells
 - Less restrictive match requirements
 - But, slow to engraft

Solution:


Improve access to transplant – improve outcomes

7 Hills Stem Cell Therapy Regimen



7HP935 is an $\alpha 4\beta 1$ agonist

+




=

An off-the-shelf generic human cord blood hematopoietic stem cell product


Outcomes

- Immediate availability
- Faster engraftment
- Simple, low cost development path



Single oral dose of 7HP935 augments stem cell transplant


Human CD34⁺ cord blood cells
plus single oral dose of 7HP935




2 weeks
→

Harvest bone marrow
and peripheral blood

Bone Marrow – human CD34⁺



Peripheral Blood – human CD45⁺



Experienced team with >5 drug approvals

Management



Upendra Marathi, PhD
President & CEO
3 new ventures, Inventor
1 NASDAQ listing



Lionel Lewis, MB BCh, MD
Chief Medical Officer
Oncologist with >40 Phase I
solid tumor studies



William Schary, Ph.D.
VP, Clin & Reg Affairs
16 New Drugs



Board of Directors



Joseph Bailes, MD
Manager, Investor
Past President,

AMERICAN SOCIETY OF
CLINICAL ONCOLOGY



Stephen A. Bent
Manager, Investor
Partner (ret.),



Kala Marathi, MBA
Manager, Investor



Charles Sheedy
Observer, Investor



Funds

- CPRIT funds MD Anderson
– ~\$0.9 million
- NIH SBIR Program funds
– \$7 million
- CPRIT & NIH
– 17.5 million

Outcomes

2014, Integrins are important for solid tumor immunity

2015-2022, Pre-Clinical & Phase I

2023-2026, 7HP111 Phase Ib/IIa

Impact of State of Texas Economic Funds



\$2 Million in 2007



\$13.5 Million in 2023



Alintegimod oral capsules

The State of Texas Economic Funds are critical in times of economic distress



- Integrins are essential to a productive immune response
- First-in-concept integrin agonists to expand the curative potential of immunotherapy for cancer
- CPRIT is essential

Upendra Marathi

upendra@7hillspharma.com

www.7hillspharma.com




**Enrichment of Stable Ytterbium-176 for Production of
No-carrier-added Lutetium-177 for Radiotherapies**




Kirk Dorius - CEO

Atom Mines

kirkdorius@atommines.com



MAGIS Isotope Separation



- MAGIS is efficient, achieving a high degree of separation with low energy input.
- MAGIS excites selected isotopes with a tuned laser and then uses magnetic fields to separate the excited isotopes.


Magnetically-Activated and Guided Isotope Separation (MAGIS)



MAGIS offers a domestic reliable supply of ^{176}Yb and other isotopes for medicine.

(12) United States Patent Raizen et al.	(10) Patent No.: US 8,672,138 B2 (45) Date of Patent: Mar. 18, 2014														
(54) ISOTOPE SEPARATION BY MAGNETIC ACTIVATION AND SEPARATION	(56) References Cited U.S. PATENT DOCUMENTS <table border="0"> <tr> <td data-bbox="639 1013 1274 1071">(71) Applicant: Board of Regents, The University of Texas System, Austin, TX (US)</td> <td data-bbox="1274 1013 1911 1071">848,600 A 3/1907 von Pirani</td> </tr> <tr> <td></td> <td>3,953,731 A 4/1976 Forsen</td> </tr> <tr> <td></td> <td>4,081,677 A 3/1978 Dawson</td> </tr> <tr> <td data-bbox="639 1099 1274 1156">(72) Inventors: Mark G. Raizen, Austin, TX (US); Bruce G. Klappauf, Austin, TX (US)</td> <td data-bbox="1274 1099 1911 1156">4,149,077 A 4/1979 Yamashita et al.</td> </tr> <tr> <td></td> <td>5,705,902 A 1/1998 Merritt et al.</td> </tr> <tr> <td></td> <td>7,323,651 B2 1/2008 Jeong et al.</td> </tr> <tr> <td data-bbox="639 1185 1274 1249">(73) Assignee: Board of Regents The University of Texas System, Austin, TX (US)</td> <td data-bbox="1274 1185 1911 1249">2011/0278203 A1 11/2011 Raizen et al.</td> </tr> </table> FOREIGN PATENT DOCUMENTS	(71) Applicant: Board of Regents, The University of Texas System, Austin, TX (US)	848,600 A 3/1907 von Pirani		3,953,731 A 4/1976 Forsen		4,081,677 A 3/1978 Dawson	(72) Inventors: Mark G. Raizen, Austin, TX (US); Bruce G. Klappauf, Austin, TX (US)	4,149,077 A 4/1979 Yamashita et al.		5,705,902 A 1/1998 Merritt et al.		7,323,651 B2 1/2008 Jeong et al.	(73) Assignee: Board of Regents The University of Texas System, Austin, TX (US)	2011/0278203 A1 11/2011 Raizen et al.
(71) Applicant: Board of Regents, The University of Texas System, Austin, TX (US)	848,600 A 3/1907 von Pirani														
	3,953,731 A 4/1976 Forsen														
	4,081,677 A 3/1978 Dawson														
(72) Inventors: Mark G. Raizen, Austin, TX (US); Bruce G. Klappauf, Austin, TX (US)	4,149,077 A 4/1979 Yamashita et al.														
	5,705,902 A 1/1998 Merritt et al.														
	7,323,651 B2 1/2008 Jeong et al.														
(73) Assignee: Board of Regents The University of Texas System, Austin, TX (US)	2011/0278203 A1 11/2011 Raizen et al.														

Stripes of Collected Yb-176



CPRIT Funding for Commercial Scale-up




MAGIS Can Separate Over 130 Isotopes of Over 30 Elements

	Element	Stable Isotopes
1	Li	6,7
2	Mg	24,25,26
3	Ar	36,38,40
4	K	39,40,41
5	Ca	40,42,43,44,46,48
6	Cr	50,52,53,54
7	Fe	54,56,57,58
8	Ni	58,60,61,62,64
9	Cu	63,65
10	Zn	64,66,67,68,70
11	Ga	69,70
12	Kr	78,80,82,83,84,86
13	Rb	85,87
14	Sr	84,86,87,88
15	Mo	92,94,95,96,97,98,100

	Element	Stable Isotopes
16	Ag	107,109
17	Cd	106,108,110,111,112,113,114,116
18	In	113,115
19	Xe	124,126,128,129,130,131,132,134,136
20	Ba	130,132,134,135,136,137,138
21	Nd	142,143,144,145,146,148,150
22	Gd	152,154,155,156,157,158,160
23	Dy	156,158,160,161,162,163,164
24	Er	162,164,166,167,168,170
25	Yb	168,170,171,172,173,174,176
26	Hg	196,198,199,200,201,202,204
27	Tl	203,205
28	Si	
29	Sn	
30	Ge	
31	Pb	

Production of Lu-177 for Cancer Beta-therapies





Kirk Dorius - CEO
Atom Mines
kirkdorius@atommines.com


PRANA THORACIC

The future of early intervention in lung cancer

LUNG CANCER BY THE NUMBERS



Lung cancer is the #1 cancer killer in the US and we don't find it early enough



More than half of patients with lung cancer die within a year of being diagnosed




New guidelines in place for 15 million Americans to be screened for lung cancer annually



<5% of eligible patients are undergoing screening

EARLY INTERVENTION IN LUNG CANCER


Physicians need a better tool to diagnose lung cancer early



ThoraCore

Prana Thoracic is developing an electro-surgical instrument intended for cylindrical, single-port excision of targeted lung tissue, using bipolar RF energy for sealing.






PIPELINE & VISION



Definitive diagnosis and molecular testing of lung abnormalities



Treatment of pulmonary metastases



Treatment of early-stage primary lung cancer in combination with ablation / drug delivery



Applications in other solid organs: breast, liver, kidney, lymph nodes.

Traction

01

Executive:

- Full Time Team of 6 Hired
- Series A Closing of \$3M; CPRIT Grant of \$3M
- 2 New SAB Member

02

Product Development:

- Completed and Tested "Alpha" Prototype
- Invention of Lung Stabilization Port for Transition to IR Suite
- 3 Additional Animal Studies Completed

03

Clinical / Regulatory:

- FDA Pre-Sub Meeting Confirmed *De Novo* Pathway
- Innovation Award at Society Meeting (ISMICS 2023)
- FIH + Pivotal Study Synopses Complete

04

Quality:

- Phase II Design Review Complete
- QMS and QMS Training Implemented (100% Complete)
- Quality Management Review Held



Meet Our Team



Joanna Nathan

Chief Executive Officer

New Ventures at J&J CDI
Venture Fellow at Mercury Fund
Director of Product Development
at Saranas



Ken Bueche

Chief Operating Officer

25 years leading first to market
innovation in regulated manufacturing
environments. Executive at various
medtech startups, Medtronic, Guidant,
and Ethyl



Rick Fischel, MD

Chief Medical Officer

20 years clinical practice as a thoracic
surgeon @ Cedars Sinai, St Joseph's and
Hoag Hospital Ran multidisciplinary
tumor boards at these hospitals



Ed Boyle, MD

Chief Scientific Officer

Founding CEO of ClearFlow
Founder of MDI Partners
Founder of Elixis (acquired by DCCA)
20 years clinical practice as a
thoracic surgeon



Lance Black, MD

Chief Clinical Strategy Officer

20 years in healthcare
Family medicine physician for USAF
Founder and CMO at XN Health
Senior Medical Director at 3ive Labs
Associate Director at TMC Innovation



Jodie Rodriguez

Sr. Director of Quality Assurance

20 years in quality assurance, including
leadership roles at SkinMedica and
Triliant Surgical
Senior Engineer at Fujifilm Diosynth



Carolyne Lu

Director of Clinical & Regulatory
Strategy

Product Development Engineer at
Procyron; innovation experience at J&J
CDI, manufacturing process experience
at Boston Scientific



Jay Salazar

Director of Product Strategy

Product Development Engineer at
J&J Center for Device Innovation



Laura Gonzalez

Product Development Engineer

R&D experience at J&J Center for Device
Innovation

Clinical Advisors



Mara Antonoff

MD Anderson

Thoracic Surgeon

Clinical focus on thoracic surgical oncology



Billy Cohn

Center for Device Innovation

Executive Director of TMC Center for Device Innovation

Founder of TVA, Sentreheart, Bivacor



Rich Miller

Penrose S Francis Health

Thoracic Surgeon

Clinical focus on thoracic surgery in community setting

CPRIT

CPRIT funding has enabled us to attract technology and funding from the coasts and hire homegrown top tier talent

Technology

ThoraCore was invented by thoracic surgeons on the West Coast and its early development was seeded by J&J

Team

Prana Thoracic's full-time team consists of locally developed talent with significant experience across medtech functions

PRANA THORACIC

The future of early intervention in lung cancer



Transforming Immuno-Oncology (IO)

Presentation to:



OCTOBER 2-3, 2023 • MOODY GARDENS HOTEL AND CONVENTION CENTER • GALVESTON, TEXAS

Oct. 2023

This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to ImmunoGenesis, Inc. (“ImmunoGenesis” or the “Company”). The information contained herein does not purport to be all-inclusive and none of the Company, its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, expressed or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.


Forward-Looking Statements

Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including general economic conditions and other risks, uncertainties and factors. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company does not undertake any duty to update these forward-looking statements.

2011-2014: Immunotherapy Revolutionizes the Treatment of Cancer for Millions of Patients



James Allison wins Nobel Prize for Discovery of CTLA-4 inhibitor



YERVOY®: CTLA-4 inhibitor approved 2011




KEYTRUDA® & OPDIVO®: PD-1 inhibitors approved 2014 & 2015



Immuno-Oncology (IO) Development has Followed the Gartner Hype Cycle for Emerging Technologies

After initial breakthrough, a “gold rush” ensued characterized by frenzied development with little scientific rationale – this has led to IO disillusionment



ImmunoGenesis is leading the path up the slope of enlightenment

ImmunoGenesis Investment Thesis

- IMGS-001 disrupts the cancer treatment landscape
 - Opportunity to more than triple sales of market leader, Keytruda (\$25B annual revenue)
 - First patient to be dosed Sept. 27
- IMGS-101(EVO) targets key immune barrier
 - \$2-5B annual revenue potential
 - First patient to be dosed in Q4 2023
- Founder is a trailblazer in immuno-oncology
- \$35M raised since founding via non-dilutive grants and convertible notes
 - Efficient use of funds (eg, \$250K monthly overhead) to ready 2 assets for clinical trials
- **Series A of \$40-50M drives \$10-30B near-term exit opportunity**

Founder: Michael A. Curran, PhD

Associate Professor of Immunology, MD Anderson



Trailblazer in Immuno-Oncology

- Played pivotal role in creating the immuno-oncology industry with Nobel Laureate, James Allison
- Invented the most effective checkpoint combination
- Extensive drug development expertise
- Highly sought after for Advisory panels – e.g., Pfizer, AstraZeneca, Merck; Pfizer tried to hire Dr. Curran multiple times to run Oncology R&D
- Curran Lab re-envisioned IO beginning in 2013
- 2019 ImmunoGenesis was born

Experienced Team Driving Results

MANAGEMENT



James A. Barlow, Jr. | CEO and President



Freddi F. O'Brien | Chief Financial Officer



Jeremy Barton, MD | Acting Chief Medical Officer



Matthew Hemberger, PhD | Senior Director, CMC & Quality



Federica Pericle, PhD | Chief Scientific Officer



Christine Gagliardi, PhD | Director, R&D



Charles Schweizer, PhD | SVP Clinical Development




Amanda Sanders | Associate Director, Clinical Operations



SCIENTIFIC, CLINICAL, & BUSINESS ADVISORS



Michael A. Curran, PhD
Founder and SAB Head



David Hong, MD
Clinical Advisor



Jacques Gaudreault
Nonclinical Consultant



Robert Stein, MD PhD
Member, Board of Directors



Current PD-1 Inhibitor Therapy Dominates IMGS-001 Resolves Major Gaps

2025 sales \$50B*


KEYTRUDA®

OPDIVO®

TECENTRIQ®

LIBTAYO®

BAVENCIO®
avelumab 20 mg/mL



IMGS-001
Re-envision and reset
the starting point for
cold tumor efficacy
>\$50B market



*GlobalData estimates.

Not Enough Patients Benefit from PD-1 Inhibitors

- Most tumors lock out T cells; current PD-1 inhibitors don't address this problem
- PD-1 inhibitors in combination with any other drugs have not solved the issue
 - Success rate: 1:287 combination trials

How does this translate into actual patient statistics?

- <45% of cancer patients can receive a PD-1 inhibitor; <20% of those respond
 - Goal of IMGS-001 is to broaden indication to upwards of 100% of patients
 - Our models indicate that IMGS-001 can drive 4-6X the response rate of current PD-1s



“Combinations with current PD-1 inhibitors are not effective... Your approach with IMGS-001 is exactly what is needed – a revolutionary PD-1 inhibitor therapy that has optimal blockade and enables the killing of immunosuppressive cells. This agent can transform cancer treatment.”

Dr. Jedd Wolchok, Current Director Weill Cornell Cancer Center
Previous 16 years Director of Immunotherapy Sloan Kettering

IMGS-001 Transforms Immuno-Oncology

- IMGS-001 engineered to optimize PD-1 blockade and address T cell lock-out
- Potential to significantly outperform Keytruda across all cancers
- Can act as the superior foundation for combination trials
- Market approval expected simultaneous to Keytruda/Opdivo loss of exclusivity

Removes barrier excluding T cells



CPRIT Grant Positioned IMGS to Transform IO

- \$15.5M CPRIT grant was first significant influx of capital into company
 - Led to additional raise of \$13.3M in convertible notes as matching funds
- Independent validation of value proposition for IMGS-001
- Facilitated the creation of a world-class team
- Led to company being headquartered at JLABs TMC
- Funded manufacturing, tox and other IND-enabling activities for IMGS-001
- Company is now positioned to bring this groundbreaking treatment to patients and completely disrupt the cancer treatment landscape



Questions?



THANK YOU



INNOVATIONS
In Cancer Prevention and Research Conference



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Coming up next:

**Reception, Gala Dinner, and
Awards Ceremony**

Francis Moody Foyer & Ballroom

Share the Experience

1

Tag us on any post from or about the Innovations VI conference. [@CPRITTEXAS](#)

2

Like and Share our posts about the conference and our grantees and grantee institutions or organizations

3

Include one of our conference hashtags listed below:

[#CPRITInnovations](#)
[#TexasCancerConference](#)
[#TexansConquerCancer](#)

    YouTube [@CPRITTEXAS](#)